Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3509106 | 0.86 | HDAC3 (0.30) | CA12CA1CA2CA9 | |
| SCHEMBL10193114 | 0.82 | CA12 (0.40) | CA12CA1CA2CA9CRHR1 | |
| SCHEMBL3507634 | 0.78 | LMNA (0.41) | CRHR1 | |
| SCHEMBL18198140 | 0.78 | ADORA2A (0.41) | CA12CA1CA2CA9CRHR1 | |
| SCHEMBL2587727 | 0.76 | LMNA (0.49) | CA12CA1CA2CA9CRHR1 | |
| SCHEMBL13169952 | 0.76 | ALDH1A1 (0.37) | CA12CA1CA2CA9CRHR1 | |
| SCHEMBL18198139 | 0.74 | ADORA2A (0.38) | CA12CA1CA2CA9PDE4B | |
| SCHEMBL8225930 | 0.73 | HPGD (0.40) | CA12CA1CA2CA9PDE4B | |
| SCHEMBL13870730 | 0.73 | KMT2A (0.39) | CA12CA1CA2CA9CRHR1 | |
| SCHEMBL16050183 | 0.72 | HPGD (0.37) | CA12CA1CA2CA9PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085555-A1 | Composition, synthesis and therapeutic applications of polyamines | MURPHY, MICHAEL A. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085555-A1 | Composition, synthesis and therapeutic applications of polyamines | PRDX5, PINK1, ARG2 | CA12 4712/4885CA1 4029/4885CA2 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.